Navigation Links
PhaseRx Announces Technology Evaluation Agreement with Monsanto
Date:1/24/2013

Seattle, WA. (PRWEB) January 24, 2013

PhaseRx, Inc., a privately held RNAi delivery technology company, announced today that it has signed a funded technology evaluation agreement with Monsanto Company for PhaseRx's delivery technologies. Through the agreement, Monsanto will evaluate PhaseRx's SMARTT Polymer Technology® for potential agricultural applications. Terms of the agreement were not disclosed.

"This agreement with Monsanto represents PhaseRx's first project in the large and growing field of agriculture," said Robert Overell, Ph.D., President and Chief Executive Officer of PhaseRx, Inc. "It also helps further validate the breadth of PhaseRx platform capabilities beyond our primary focus applications."

About PhaseRx

PhaseRx is a privately held RNAi therapeutics company using its proprietary delivery technology to develop personalized medicines against key oncology targets. RNAi therapeutics represent a new class of pharmaceuticals with significant market potential, which has been hindered to date by the lack of effective delivery technology. PhaseRx's SMARTT Polymer Technology® offers effective intracellular RNAi delivery, broad candidate and therapeutic applicability, and robust and reproducible manufacturing. For more information about PhaseRx, please visit http://www.phaserx.com.

###

Read the full story at http://www.prweb.com/releases/2013/1/prweb10353976.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... October 01, 2014 Slone Partners ... Therapeutics, Healthcare IT, and Laboratory Testing industries, reported a ... at the director level and above from July 2013 ... stay on top of rapid breakthroughs in diagnostics, reimbursement ... diagnostic companies have been forced to fold, consolidate, or ...
(Date:9/30/2014)... German . , ... in a semiconductor layer. Quantum dots are small structures that ... a short laser pulse is fired at the photonic crystal, ... a change in the electromagnetic field around it. This change ... by the dot. As soon as the refractive index recovers ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... Hungary, May 9 Genetic,Immunity, a US/Hungarian clinical-stage ... for targeted immune amplification, announced,today that the Company ... 5th,Annual Global Healthcare Conference to be held May ... in Monte Carlo, Monaco. The Company,s President,and Chief ...
... Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) announced today ... by 10%, taking its total holdings to 61% ... Diagnostic Technique for pulmonary,related medical conditions., Pulmo ... the Molecular,Imaging technology, developed and owned by PulmoScience, ...
... Md., May 9 Novavax, Inc. (Nasdaq:,NVAX) today announced financial ... of $7.8 million ($0.13 loss per share) for the first,quarter ... ($0.14 loss per,share) for the first quarter of 2007. Total ... million compared to $46.5 million as of,December 31, 2007. The ...
Cached Biology Technology:Genetic Immunity To Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Pulmo BioTech Announces an Increase in its Stake in PulmoScience 2Pulmo BioTech Announces an Increase in its Stake in PulmoScience 3Novavax Reports First Quarter 2008 Financial Results 2Novavax Reports First Quarter 2008 Financial Results 3Novavax Reports First Quarter 2008 Financial Results 4Novavax Reports First Quarter 2008 Financial Results 5Novavax Reports First Quarter 2008 Financial Results 6Novavax Reports First Quarter 2008 Financial Results 7Novavax Reports First Quarter 2008 Financial Results 8
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... with IVF? Here,s some hope: A new research report ... FASEB Journal , explains how scientists developed a ... which induced embryo development in human and mouse eggs ... the sperm cell during fertilization. , "We believe that ... shift in our understanding of human fertilization by providing ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... at The University of Manchester believe injections of tiny ... in the treatment of chronic lower back pain. , ... Professor Tony Freemont from The Faculty of Medical and ... and stiffen when injected into a damaged area. ...
... its new cigarette brand seems to promise a lot. "May ... boasts on its Web site, making it a natural choice ... are interested in a cigarette that responds to concerns about ... print ad for the brand, has crowed "All of the ...
... researchers have discovered a genetic cause of a mysterious ... using words. The illness, Primary Progressive Aphasia, differs from ... In PPA, a little known form of dementia, ... speech. , "This discovery, for the first ...
Cached Biology News:Swell gel could bring relief to back pain sufferers 2New cigarette designs don't offer lower predicted cancer risks 2New cigarette designs don't offer lower predicted cancer risks 3Researchers discover genetic cause for word-finding disease 2
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... Mut S is a member of a class ... of the DNA sequence. Mut S plays an ... DNA ,replication, in transcription-coupled nucleotide excision repair and ... bacteria. Mut S binds to DNA specifically at ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: